High level of anti-drug antibodies after intra-articular injection of anti-TNF

被引：1
|
作者：
Zufferey, Pascal [1 ]
Perreau, Mathieu [2 ]
So, Alexander [1 ]
机构：
[1] CHU Vaudois, Dept Appareil Locomoteur, Serv Rhumatol, CH-1011 Lausanne, Switzerland
[2] CHU Vaudois, Serv Immunol, CH-1011 Lausanne, Switzerland
来源：
RHEUMATOLOGY | 2015年 / 54卷 / 12期
关键词：
PERSPECTIVE;
D O I：
10.1093/rheumatology/kev325
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2291 / 2292
页数：2
相关论文
共 50 条
  • [31] SWITCHING OUT OF CLASS OR TO ANOTHER ANTI-TNF AGENT IS THE BEST STRATEGY FOR CLINICAL EFFICACY AND TREATMENT PERSISTENCE IN IBD PATIENTS WITH ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF
    Anjie, Suzanne I.
    Hanzel, Jurij
    Gecse, Krisztina B.
    D'Haens, Geert
    Brandse, Johannan F.
    GASTROENTEROLOGY, 2023, 164 (06) : S1120 - S1121
  • [32] Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis.
    Jani, Meghna
    Chinoy, Hector
    Warren, Richard B.
    Griffiths, Christopher E. M.
    Morgan, Ann W.
    Wilson, Anthony G.
    Hyrich, Kimme L.
    Isaacs, John
    Plant, Darren
    Barton, Anne
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1278 - S1278
  • [33] Interest in the addition of azathioprine (AZA) to the switch of anti-TNF in IBD patients in loss of response with undetectable anti-TNF trough levels and anti-drug antibodies: A prospective randomised trial
    Roblin, X.
    Paul, S.
    Boschetti, G.
    Phelip, J. M.
    Del Tedesco, E.
    Berger, A.
    Nancey, S.
    Williet, N.
    Flourie, B.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S414 - S415
  • [34] INTEREST IN THE ADDITION OF AZATHIOPRINE (AZA) TO THE SWITCH OF ANTI-TNF IN IBD PATIENTS IN CLINICAL RELAPSE WITH UNDETECTABLE ANTI-TNF TROUGH LEVELS AND ANTI-DRUG ANTIBODIES: A PROSPECTIVE RANDOMIZED TRIAL
    Roblin, Xavier
    Paul, Stephane
    Nancey, Stephane
    Williet, Nicolas
    Flourie, Bernard
    GASTROENTEROLOGY, 2018, 154 (06) : S84 - S84
  • [35] Immunogenicity, the elephant in the room. Comment on “Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases”
    John Pixley
    Clinical Rheumatology, 2013, 32 : 1413 - 1413
  • [36] Immunogenicity, the elephant in the room. Comment on "Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases"
    Pixley, John
    CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1413 - 1413
  • [37] The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation
    Berkhout, L. C.
    Vogelzang, E. H.
    Hart, M. H.
    Loeff, F. C.
    Dijk, L.
    Derksen, N. I. L.
    Wieringa, R.
    van Leeuwen, W. A.
    Krieckaert, C. L. M.
    de Vries, A.
    Nurmohamed, M. T.
    Wolbink, G. J.
    Rispens, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (02) : 306 - 313
  • [38] THE EFFECT OF CERTOLIZUMAB DRUG CONCENTRATION AND ANTI-DRUG ANTIBODIES ON TNF NEUTRALISATION
    Berkhout, L. C.
    Vogelzang, E. H.
    Hart, M. H.
    Derksen, N. I.
    Wieringa, R.
    van Leeuwen, W. A.
    Krieckaert, C. L.
    de Vries, A.
    Nurmohamed, M. T.
    Wolbink, G.
    Rispens, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 322 - 322
  • [39] Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis
    Hwang, Jiwon
    Kim, Hye-Mi
    Jeong, Hyemin
    Lee, Jaejoon
    Ahn, Joong Kyong
    Koh, Eun-Mi
    Kang, Eun-Suk
    Cha, Hoon-Suk
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2017, 57 (04) : 311 - 319
  • [40] HLA-DQA1*05 and development of anti-drug antibodies in anti-TNF treated patients with inflammatory bowel disease
    Lopez-Blanco, Ruben
    Mendez-Lopez, Isabel-Maria
    Recio-Romero, Rafael
    Luque-Fernandez, Rosario
    Caballero-Gonzalez, Abelardo
    Torio-Ruiz, Alberto
    HLA, 2022, 99 (05) : 539 - 540
12345